DelNova: Addressing complications from Botox (217)
DelNova

DelNova, Inc. is a biopharmaceutical company focused on addressing unmet medical needs. DelNova is resolving complications arising from botulinum toxin therapies (eg. Botox®). The first product under development, ReViVox™ is based on a clinically validated drug currently approved for a different medical use and route of administration. The novel formulation will manage undesirable side effects resulting from neurotoxin injections in both medical and cosmetic applications.


– Apple
– Spotify

Facebook
Twitter
LinkedIn

Recent Posts

Fast Yes Fast No – Tools for Effectively Raising Capital

The kiss of death for any startup raising capital is hearing “maybe.” As much as…

DelNova: Addressing complications from Botox (217)

DelNova, Inc. is a biopharmaceutical company focused on addressing unmet medical needs. DelNova is resolving…

ParaNano: Applying nano technology to wound care (216)

ParaNano Wound Care (PWC) solves a global problem in treatment of infection in chronic wounds:…